A pre-earnings headline says Biogen is expected to beat estimates, but the supplied information includes neither the estimates nor the company’s Q3 results.
An October 21 headline says Biogen Inc. is expected to beat earnings estimates ahead of its Q3 release. It gives no earnings figures, estimate comparisons, or release date, so the claim remains an expectation, not a reported result. Biogen’s latest supplied close was US$243.44.
Investor takeaway: The headline describes an expected earnings beat. The available information does not show whether Biogen ultimately beat estimates.
Advertisement
Biogen Inc
BIIB.US
BIIB.US
Biogen Inc
WealthAwesomeMarket cap
$35.61B
P/E
42.8x
52W high
$244.65
52W low
$138.00
1W change
+3.50%
Beta
0.09
Analyst Price Targets
Based on 36 analysts covering BIIB · as of Oct 22, 2026
Wall Street analysts forecast BIIB stock price to rise 2.3% over the next 12 months.
Consensus
Buy4.17 / 5.00
Avg. Target
C$246.54
+2.3% Upside
Previously C$243.89 on Oct 21, 2026
Current Price
C$240.98
Last close
Analyst Breakdown (36 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BIIB's historical volatility
30-Day Vol
23.4%
Annualized
90-Day Vol
35.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$288.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$255.76 | C$235.90 – C$277.29 |
| 60 trading days | C$271.45 | C$242.12 – C$304.32 |
| 90 trading days | C$288.09 | C$250.46 – C$331.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
US$243.44 latest close
Biogen’s latest supplied close was US$243.44, near the top of its US$138.00–US$244.65 52-week range. The share price does not confirm the earnings expectation.
Bull case
The headline points to an expected earnings beat, and the supplied performance data show BIIB.US shares gained 35.52% year to date.
Bear case
The available information includes no earnings estimates, company results, or explanation for the expected beat. The headline’s claim remains unverified.
What happened: an expectation, not a reported result
Advertisement
The October 21 headline says Biogen is expected to beat earnings estimates ahead of its Q3 release. The supplied information does not say which earnings measure or estimates the headline refers to, what supports the expectation, or when the results will be released. It also includes no Q3 results. So the headline describes an expectation, not a confirmed beat. A separate October 21 headline mentions Biogen in a Zacks Analyst Blog with several other companies, but provides no additional company-specific earnings figures.
What the numbers show: shares near their 52-week high
Biogen’s latest supplied close was US$243.44, within its US$138.00–US$244.65 52-week range. The stock gained 10.00% over one month and 35.52% year to date, while its one-day return was down 0.87%. Latest volume was 43,575 shares, compared with a 20-day average of 1,270,740 shares; the supplied volume comparison was 0.64x. These figures describe trading activity, not whether Biogen beat earnings estimates. Find more company and quote information on the Biogen stock page.
What to watch next: the Q3 results and estimates
The next key information is Biogen’s Q3 release and the estimates used to judge whether it beat expectations. The supplied facts include neither the release date nor the relevant estimates, so they don’t establish the outcome. Once both are available, investors can compare the reported figures with the estimates. The headline alone does not confirm a beat. For more stock information, visit the Biogen stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
